TY - JOUR
T1 - Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
AU - Wujanto, Caryn
AU - Vellayappan, Balamurugan
AU - Siva, Shankar
AU - Louie, Alexander V.
AU - Guckenberger, Matthias
AU - Slotman, Ben J.
AU - Onishi, Hiroshi
AU - Nagata, Yasushi
AU - Liu, Mitchell
AU - Lo, Simon S.
PY - 2019/11/12
Y1 - 2019/11/12
N2 - Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated with palliative intent platinum-based chemotherapy alone. Recent advances in imaging and therapeutic strategy have identified a subset of patients with limited metastases who may benefit from early local ablative therapy with either surgery or radiotherapy, in addition to standard treatment. Stereotactic body radiotherapy (SBRT) is increasingly used in the treatment of extra-cranial oligometastatic NSCLC (OM-NSCLC) due its non-invasive conduct and ability to deliver high doses. Clinical evidence supporting the use of SBRT in OM-NSCLC is emerging and consistently demonstrates significant benefit in local control and progression-free survival. Here, we discuss the definition of oligometastases (OM), review current available data on SBRT treatment in extra-cranial OM-NSCLC including evidence for site-specific SBRT in lung, liver, and adrenal metastases.
AB - Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated with palliative intent platinum-based chemotherapy alone. Recent advances in imaging and therapeutic strategy have identified a subset of patients with limited metastases who may benefit from early local ablative therapy with either surgery or radiotherapy, in addition to standard treatment. Stereotactic body radiotherapy (SBRT) is increasingly used in the treatment of extra-cranial oligometastatic NSCLC (OM-NSCLC) due its non-invasive conduct and ability to deliver high doses. Clinical evidence supporting the use of SBRT in OM-NSCLC is emerging and consistently demonstrates significant benefit in local control and progression-free survival. Here, we discuss the definition of oligometastases (OM), review current available data on SBRT treatment in extra-cranial OM-NSCLC including evidence for site-specific SBRT in lung, liver, and adrenal metastases.
KW - lung cancer
KW - non-small cell lung cancer
KW - oligometastases
KW - oligometastatic disease
KW - stereotactic body radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85076027517&partnerID=8YFLogxK
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076027517&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31799188
U2 - https://doi.org/10.3389/fonc.2019.01219
DO - https://doi.org/10.3389/fonc.2019.01219
M3 - Review article
C2 - 31799188
SN - 2234-943X
VL - 9
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1219
ER -